WT Wealth Management raised its position in VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) by 6.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 53,660 shares of the company’s stock after purchasing an additional 3,424 shares during the quarter. VanEck Pharmaceutical ETF accounts for approximately 1.2% of WT Wealth Management’s portfolio, making the stock its 19th largest holding. WT Wealth Management owned about 0.70% of VanEck Pharmaceutical ETF worth $5,080,000 at the end of the most recent quarter.
Other institutional investors have also modified their holdings of the company. Thrivent Financial for Lutherans acquired a new position in shares of VanEck Pharmaceutical ETF during the second quarter worth about $16,088,000. Northwestern Mutual Wealth Management Co. lifted its position in shares of VanEck Pharmaceutical ETF by 1.7% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 160,039 shares of the company’s stock worth $14,641,000 after purchasing an additional 2,694 shares in the last quarter. Financial Partners Group Inc purchased a new position in shares of VanEck Pharmaceutical ETF in the second quarter valued at $8,701,000. Adamsbrown Wealth Consultants LLC acquired a new stake in VanEck Pharmaceutical ETF during the 3rd quarter valued at $7,030,000. Finally, J.Safra Asset Management Corp increased its stake in VanEck Pharmaceutical ETF by 5.9% during the 2nd quarter. J.Safra Asset Management Corp now owns 73,609 shares of the company’s stock worth $6,734,000 after buying an additional 4,084 shares during the period.
VanEck Pharmaceutical ETF Trading Down 0.0 %
NASDAQ:PPH traded down $0.02 on Tuesday, reaching $93.61. The stock had a trading volume of 136,234 shares, compared to its average volume of 139,085. VanEck Pharmaceutical ETF has a 12-month low of $74.05 and a 12-month high of $99.51. The stock has a market cap of $719.86 million, a P/E ratio of 21.04 and a beta of 0.72. The company has a 50-day moving average of $96.22 and a 200 day moving average of $92.47.
VanEck Pharmaceutical ETF Profile
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
Recommended Stories
- Five stocks we like better than VanEck Pharmaceutical ETF
- Learn Technical Analysis Skills to Master the Stock Market
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Want to see what other hedge funds are holding PPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report).
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.